Ruth O'Regan, MD

Articles

Dr. O’Regan on the Utility of CDK4/6 Inhibitors in Breast Cancer

August 31st 2020

Ruth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.

Dr. O'Regan on Emerging CDK4/6 Combinations in Breast Cancer

August 14th 2020

Ruth O’Regan, MD, discusses emerging CDK4/6 inhibitor combinations in breast cancer.

Dr. O’Regan on Biomarkers of Response to CDK4/6 Inhibitors in Breast Cancer

July 31st 2020

Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.

Dr. O'Regan on Biosimilar Education in Breast Cancer

December 19th 2019

Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.

Dr. O'Regan on Prognostic Value of pCR in HER2+ Breast Cancer

November 9th 2019

Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.

Dr. O'Regan on Future of Chemotherapy in Breast Cancer

December 11th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.

Dr. O'Regan on Impact of Targeted Agents in HER2+ Breast Cancer

November 22nd 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the impact of targeted agents in HER2-positive breast cancer.

Dr. O'Regan Discusses Biosimilar Education in Oncology

October 29th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biosimilar education in oncology.

Dr. O'Regan on the Status of Biosimilars in Oncology

October 17th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.

Dr. O'Regan on Biomarker Research in Breast Cancer

October 27th 2017

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.